An Extension Study of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
This study is designed to evaluate the safety of linifanib in subjects with advanced or
metastatic solid tumors.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety.
The investigators will monitor each subject for clinical and lab evidence of adverse events on a routine basis through out the study. The investigators will question each subject regarding any adverse effects that they have experienced and record any events on the care report forms. All adverse events will be followed to a satisfactory clinical resolution.
All adverse events occuring through the Final Visit will be reported.
Mark D. McKee, MD
United States: Food and Drug Administration
|Site Reference ID/Investigator# 53006||Tucson, Arizona 85724-5024|
|Site Reference ID/Investigator# 53003||Baltimore, Maryland 21231|
|Site Reference ID/Investigator# 62482||Detroit, Michigan 48201|
|Site Reference ID/Investigator# 53004||Lebanon, New Hampshire 03756-0001|
|Site Reference ID/Investigator# 53007||San Antonio, Texas 78229|
|Site Reference ID/Investigator# 53008||Tacoma, Washington 98405|
|Site Reference ID/Investigator# 53005||Madison, Wisconsin 53792|